🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs
5,427

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Page 101 of 114

  1. Vortioxetine

    The University of Hong Kong

    Cannabis Use Disorder

    phase 3 small molecule completed

    1 trial

  2. Vortioxetine 10 mg/day

    Takeda

    Depressive Disorder, Major

    phase 3 small molecule completed

    2 trials

  3. Vortioxetine tablets

    Takeda

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  4. Vosoritide

    BioMarin Pharmaceutical Australia Pty Ltd

    Hypochondroplasia

    phase 3 small molecule active

    3 trials

  5. Voucher-Based Reinforcement Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-related Disorders

    phase 3 other completed

    1 trial

  6. Voxzogo 0.4 mg powder and solvent for solution for injection, Voxzogo 0.56 mg powder and solvent for solution for injection, Voxzogo 1.2 mg powder and solvent for solution for injection

    BioMarin Pharmaceutical Australia Pty Ltd

    Hypochondroplasia

    phase 3 small molecule active

    1 trial

  7. Voxzogo 1.2 mg powder and solvent for solution for injection, Voxzogo 0.4 mg powder and solvent for solution for injection, Voxzogo 0.56 mg powder and solvent for solution for injection

    BioMarin Pharmaceutical Australia Pty Ltd

    Achondroplasia

    phase 3 small molecule active

    1 trial

  8. Voxzogo 1.2 mg powder and solvent for solution for injection, powder and solvent for solution for injection, Voxzogo 0.56 mg powder and solvent for solution for injection

    BioMarin Pharmaceutical Australia Pty Ltd

    Hypochondroplasia

    phase 3 small molecule active

    1 trial

  9. Vutrisiran

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

    phase 3 small molecule active

    2 trials

  10. Vyloy 100 mg powder for concentrate for solution for infusion., OXALIPLATIN, FOLINIC ACID, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CAPECITABINE, FLUOROURACIL, KEYTRUDA 25 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion., Vyloy 100 mg powder for concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion., Sodium chloride 0.9% intravenous infusion, ASP8951, CAPECITABINE, KEYTRUDA 25 mg/mL concentrate fo

    Astellas Pharma GmbH

    Gastroesophageal Junction Adenocarcinoma, Gastric Cancer, Gastric Adenocarcinoma

    phase 3 small molecule active

    1 trial

  11. Vyvanse (lisdexamfetamine dimesylate)

    Takeda

    ADHD

    phase 3 small molecule completed

    1 trial

  12. Vyvgart 1 000 mg solution for injection

    argenx

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  13. Vyvgart 1 000 mg solution for injection in pre-filled syringe, Placebo PH20 SC

    argenx

    Ocular Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  14. Vyvgart 1 000 mg solution for injection in pre-filled syringe, Placebo for efgartigimod

    argenx

    Thyroid Eye Disease (TED)

    phase 3 small molecule active

    1 trial

  15. Vyvgart 20 mg/mL concentrate for solution for infusion

    argenx

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  16. Vyvgart 20 mg/mL concentrate for solution for infusion

    argenx

    Generalized Myasthenia Gravis (gMG)

    phase 3 small molecule active

    1 trial

  17. Vyxeos

    Jazz Pharmaceuticals Ireland Limited

    Acute Myeloid Leukaemia

    phase 3 small molecule active

    1 trial

  18. Walvax PCV13-TT

    Biotech Pharmaceutical Co.,

    Pneumococcal Disease, Invasive

    phase 3 mab active

    1 trial

  19. Warfarin

    United Therapeutics Europe Ltd

    Subsegmental Pulmonary Embolism Nos

    phase 3 small molecule active

    1 trial

  20. Warfarin

    Boehringer Ingelheim

    Thromboembolism

    phase 3 small molecule completed

    1 trial

  21. Warfarin Sodium

    Hospital Authority, Hong Kong

    Indications for Warfarin Therapy

    phase 3 small molecule active

    1 trial

  22. Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen, Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1.7 mg FlexTouch solution for injection in pre-filled pen, Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, KAI-9531, Wegovy 1 mg FlexTouch solution for injection in pre-filled pen, KAI-9531, KAI-9531

    Kailera Therapeutics

    Obesity

    phase 3 small molecule active

    1 trial

  23. Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen, Placebo Semaglutide, Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen, Placebo NNC0487 0111 B, Wegovy 1 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1.7 mg FlexTouch solution for injection in pre-filled pen, NNC0487-0111 B 10144, NNC0487-0111 B 10145, NNC0487-0111 B 10146, NNC0487-0111 B 10141, NNC0487-0111 B 10142, NNC0487-0111 B 10143

    NovoThirteen

    Participants with overweight or obesity, and type 2 diabetes

    phase 3 small molecule active

    1 trial

  24. Wegovy 2.4 mg solution for injection in pre-filled pen, Rybelsus 14 mg tablets, Clopidogrel Medreg 75 mg filmom obalené tablety, Wegovy 0.25 mg solution for injection in pre-filled pen, Wegovy 0.5 mg solution for injection in pre-filled pen, Wegovy 1 mg solution for injection in pre-filled pen, Rybelsus 7 mg tablets, Wegovy 1.7 mg solution for injection in pre-filled pen, Acetylsalicylic acid Krka 100 mg enterotabletter, Rybelsus 3 mg tablets

    Istituto Gentili S.r.l.

    Diabetes Mellitus, Cardiovascular disease, Overweight (BMI ≥27 kg/m²), Obesity (BMI≥30kg/m2)

    phase 3 small molecule active

    1 trial

  25. Wheat Soy Blend (WSB++)

    United Therapeutics Europe Ltd

    Stunting

    phase 3 other completed

    1 trial

  26. White opaque capsule filled with a white to off- white powder, eRapa

    Biodexa Pharmaceuticals Plc

    Familial adenomatous polyposis (FAP)

    phase 3 small molecule active

    1 trial

  27. Wobenzym® N

    Atrium Therapeutics

    Knee Osteoarthritis

    phase 3 other terminated

    1 trial

  28. Wumeiwan Jiawei Fang

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Dry Eye Syndromes

    phase 3 small molecule active

    1 trial

  29. XALKORI 200 mg hard capsules, Alecensa 150 mg hard capsules, XALKORI 200 mg hard capsules, Alectinib (Alecensa), XALKORI 250 mg hard capsules, XALKORI 250 mg hard capsules

    Hoffmann-La Roche

    Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  30. XALKORI 250 mg hard capsules, XALKORI 200 mg hard capsules, Repotrectinib (TPX-0005), Repotrectinib (TPX-0005)

    Bristol-Myers Squibb Australia Pty Ltd

    Non small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  31. XALKORI 250 mg hard capsules, XALKORI 250 mg hard capsules, XALKORI 200 mg hard capsules, Rozlytrek, Rozlytrek, Rozlytrek, Rozlytrek 100 mg hard capsules, Rozlytrek, Rozlytrek 200 mg hard capsules, Rozlytrek, Rozlytrek, Rozlytrek, Rozlytrek, XALKORI 200 mg hard capsules, Rozlytrek, Rozlytrek

    Hoffmann-La Roche

    Non-small cell lung cancer with ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) gene rearrangements

    phase 3 small molecule active

    1 trial

  32. XELJANZ 1 mg/mL oral solution, XELJANZ 1 mg/mL oral solution, XELJANZ 1 mg/mL oral solution, Tofacitinib citrate, Tofacitinib citrate, XELJANZ 1 mg/mL oral solution

    Pfizer Australia Pty Ltd

    Ulcerative Colitis (UC)

    phase 3 small molecule active

    1 trial

  33. XEN1101

    Xenon Pharmaceuticals

    Focal Epilepsy

    phase 3 small molecule active

    2 trials

  34. XEN1101

    Xenon Pharmaceuticals

    Primary Generalized Tonic-Clonic Seizures

    phase 3 small molecule active

    1 trial

  35. XEN1101

    Xenon Pharmaceuticals

    Focal Onset Seizures

    phase 3 small molecule active

    2 trials

  36. XEN45

    Allergan Pharmaceuticals International Limited

    Glaucoma

    phase 3 other completed

    1 trial

  37. XEN496

    Xenon Pharmaceuticals

    Epilepsy

    phase 3 small molecule terminated

    2 trials

  38. XEOMIN 100 unités, poudre pour solution injectable

    Pari Pharma GmbH

    PANCREATIC FISTULA

    phase 3 small molecule active

    1 trial

  39. XEOMIN 200 V pulveris injekciju šķīduma pagatavošanai, Placebo to NT201, XEOMIN, 200 jednostek, proszek do sporządzania roztworu do wstrzykiwań

    Merz Pharmaceuticals GmbH

    Pediatric lower limb (LL) spasticity (SP) caused by cerebral palsy (CP)

    phase 3 small molecule active

    1 trial

  40. XEOMIN 200 jednotek prášek pro injekční roztok, XEOMIN, 200 jednostek, proszek do sporządzania roztworu do wstrzykiwań, XEOMEEN 200 eenheden poeder voor oplossing voor injectie, XEOMIN 200 egység por oldatos injekcióhoz, XEOMIN 200 jednotiek prášok na injekčný roztok, XEOMIN 200 unidades polvo para solución inyectable, XEOMEEN 200 unités poudre pour solution injectable, XEOMIN 200 Einheiten Pulver zur Herstellung einer Injektionslösung, XEOMIN 200 unités, poudre pour solution injectable, XEOMIN, 200 unità,

    Merz Pharmaceuticals GmbH

    Lower limb spasticity

    phase 3 small molecule active

    1 trial

  41. XEOMIN 200 unités, poudre pour solution injectable, Placebo of Xeomin 200 U

    Pari Pharma GmbH

    Adult patients with indication for conventional cardiac surgery (CABG, aortic replacement, or ascending aorta surgery)

    phase 3 small molecule active

    1 trial

  42. XL092, BELZUTIFAN, XL092, XL092, Placebo to Zanzalintinib

    Merck Sharp and Dohme

    Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  43. XPF-010

    Xenon Pharmaceuticals

    Depressive episodes associated with Bipolar disorder I or II (Bipolar Depression)

    phase 3 small molecule active

    1 trial

  44. XPF-010, Placebo to match XPF-010

    Xenon Pharmaceuticals

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  45. XR-NTX

    BRIGHT MINDS BIOSCIENCES INC.

    Opiate Addiction

    phase 3 small molecule completed

    1 trial

  46. Xanomeline and Trospium Chloride Capsules

    Bristol-Myers Squibb Australia Pty Ltd

    Schizophrenia

    phase 3 small molecule completed

    1 trial

  47. Xevinapant (Debio 1143)

    Serono Europe Limited

    Squamous Cell Carcinoma of the Head and Neck

    phase 3 small molecule terminated

    1 trial

  48. Xiang-Sha-Liu-Jun-Zi-Tang

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Irritable Bowel Syndrome

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.